Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
67
ARTV Quote, Financials, Valuation and Earnings
Last price:
$3.69
Seasonality move
:
-1.06%
Day range:
$3.51 - $3.79
52-week range:
$1.47 - $13.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
46.79x
P/B ratio:
0.71x
Volume:
62K
Avg. volume:
246K
1-year change:
-70.32%
Market cap:
$92M
Revenue:
$251K
EPS (TTM):
-$3.25
Analysts' Opinion
-
Consensus RatingArtiva Biotherapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.00, Artiva Biotherapeutics, Inc. has an estimated upside of 350.33% from its current price of $3.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $3.78.
Fair Value
-
According to the consensus of 5 analysts, Artiva Biotherapeutics, Inc. has 350.33% upside to fair value with a price target of $17.00 per share.
ARTV vs. S&P 500
-
Over the past 5 trading days, Artiva Biotherapeutics, Inc. has overperformed the S&P 500 by 5.32% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Artiva Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Artiva Biotherapeutics, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Artiva Biotherapeutics, Inc. reported revenues of --.
Earnings Growth
-
Artiva Biotherapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Artiva Biotherapeutics, Inc. reported earnings per share of -$0.88.
Enterprise value:
-19.3M
EV / Invested capital:
-0.14x
Price / LTM sales:
46.79x
EV / EBIT:
--
EV / Revenue:
31.29x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
0.24x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.5M
Return On Assets:
-41.91%
Net Income Margin (TTM):
-1351.52%
Return On Equity:
-47.44%
Return On Invested Capital:
-43.85%
Operating Margin:
-5773.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $30.4M | $26.9M | -- | -- | -- | |
| Gross Profit | $29M | $24.5M | -$2.5M | -$627K | -$662K | |
| Operating Income | -$30.6M | -$38.8M | -$86.3M | -$18.5M | -$22.9M | |
| EBITDA | -$29.2M | -$36.4M | -$83.8M | -$17.9M | -$22.2M | |
| Diluted EPS | -$1.82 | -$1.82 | -$3.25 | -$0.72 | -$0.88 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $171.5M | -- | -- | $150.6M | $129.5M | |
| Total Assets | $178.2M | -- | -- | $225.6M | $148.9M | |
| Current Liabilities | $15.6M | -- | -- | $13.3M | $11.1M | |
| Total Liabilities | $257.4M | -- | -- | $24.6M | $19.6M | |
| Total Equity | -$79.2M | -- | -- | $201M | $129.2M | |
| Total Debt | -- | -- | -- | $11.4M | $8.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$46.4M | -$51.1M | -$76.7M | -$11.6M | -$19.2M | |
| Cash From Investing | -$23.9M | -$122.2M | $46.4M | -$130.6M | $16.3M | |
| Cash From Financing | $23.1M | $163.2M | $100K | $163.9M | -$37K | |
| Free Cash Flow | -$49.6M | -$52.3M | -$78.9M | -$11.7M | -$19.8M | |
ARTV
Sector
Market Cap
$92M
$28.4M
Price % of 52-Week High
28.73%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
0.63%
-1.32%
1-Year Price Total Return
-70.32%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.52
200-day SMA
Buy
Level
$2.96
Bollinger Bands (100)
Buy
Level
2.53 - 3.89
Chaikin Money Flow
Sell
Level
-44.7M
20-day SMA
Buy
Level
$3.50
Relative Strength Index (RSI14)
Buy
Level
53.14
ADX Line
Buy
Level
15.03
Williams %R
Sell
Level
-18.5393
50-day SMA
Buy
Level
$3.59
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
85.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.6956)
Sell
CA Score
(Annual)
Level (-1.1948)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.4588)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, ARTV has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARTV average analyst price target in the past 3 months is $17.00.
-
Where Will Artiva Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Artiva Biotherapeutics, Inc. share price will rise to $17.00 per share over the next 12 months.
-
What Do Analysts Say About Artiva Biotherapeutics, Inc.?
Analysts are divided on their view about Artiva Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Artiva Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Artiva Biotherapeutics, Inc.'s Price Target?
The price target for Artiva Biotherapeutics, Inc. over the next 1-year time period is forecast to be $17.00 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARTV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Artiva Biotherapeutics, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARTV?
You can purchase shares of Artiva Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Artiva Biotherapeutics, Inc. shares.
-
What Is The Artiva Biotherapeutics, Inc. Share Price Today?
Artiva Biotherapeutics, Inc. was last trading at $3.69 per share. This represents the most recent stock quote for Artiva Biotherapeutics, Inc.. Yesterday, Artiva Biotherapeutics, Inc. closed at $3.78 per share.
-
How To Buy Artiva Biotherapeutics, Inc. Stock Online?
In order to purchase Artiva Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ARTV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ARTV
Sector
P/E ratio
--
23.66x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.71x
1.84x
Price / LTM sales
46.79x
1.60x
Growth Metrics
ARTV
Sector
Revenue growth
126.13%
4.85%
Earnings growth
-22.24%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.80
-$0.20
Profitability
ARTV
Sector
Profitability FY 2024
-$2.2M
$3.6M
Return on invested capital
-43.85%
-30.98%
Return on assets
-41.91%
-27.62%
Return on equity
-47.44%
-36.69%
Earnings Date
Last Earnings Date
Aug
7
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
ARTV
Sector
Total cash
$123M
$27.2M
Short term investments
$145.2M
$25.7M
Total assets
$209.6M
$79.9M
Long term debt
$8.6M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
